J u m p t o c o n t e n t
M a i n m e n u
M a i n m e n u
N a v i g a t i o n
● M a i n p a g e ● C o n t e n t s ● C u r r e n t e v e n t s ● R a n d o m a r t i c l e ● A b o u t W i k i p e d i a ● C o n t a c t u s ● D o n a t e
C o n t r i b u t e
● H e l p ● L e a r n t o e d i t ● C o m m u n i t y p o r t a l ● R e c e n t c h a n g e s ● U p l o a d f i l e
S e a r c h
Search
A p p e a r a n c e
● C r e a t e a c c o u n t ● L o g i n
P e r s o n a l t o o l s
● C r e a t e a c c o u n t ● L o g i n
P a g e s f o r l o g g e d o u t e d i t o r s l e a r n m o r e ● C o n t r i b u t i o n s ● T a l k
( T o p )
1 R e f e r e n c e s
2 E x t e r n a l l i n k s
T o g g l e t h e t a b l e o f c o n t e n t s
M A S 1 o n c o g e n e
2 l a n g u a g e s
● С р п с к и / s r p s k i ● S r p s k o h r v a t s k i / с р п с к о х р в а т с к и
E d i t l i n k s
● A r t i c l e ● T a l k
E n g l i s h
● R e a d ● E d i t ● V i e w h i s t o r y
T o o l s
T o o l s
A c t i o n s
● R e a d ● E d i t ● V i e w h i s t o r y
G e n e r a l
● W h a t l i n k s h e r e ● R e l a t e d c h a n g e s ● U p l o a d f i l e ● S p e c i a l p a g e s ● P e r m a n e n t l i n k ● P a g e i n f o r m a t i o n ● C i t e t h i s p a g e ● G e t s h o r t e n e d U R L ● D o w n l o a d Q R c o d e ● W i k i d a t a i t e m
P r i n t / e x p o r t
● D o w n l o a d a s P D F ● P r i n t a b l e v e r s i o n
A p p e a r a n c e
F r o m W i k i p e d i a , t h e f r e e e n c y c l o p e d i a
The MAS1 oncogene (MAS receptor ) is a G protein-coupled receptor [1] [2] angiotensin II metabolite angiotensin (1-7) .[3] [4] angiotensin II receptor . Hence, MAS1 receptor agonists have similar therapeutic effects to angiotensin II receptor antagonists , including lowering of blood pressure.[5]
References [ edit ]
^ Nunes-Silva A, Rocha GC, Magalhaes DM, Vaz LN, Salviano de Faria MH, Simoes e Silva AC (November 2017). "Physical Exercise and ACE2-Angiotensin-(1-7)-Mas Receptor Axis of the Renin Angiotensin System". Protein and Peptide Letters . 24 9 ). Bentham Science Publishers Ltd.: 809–816. doi :10.2174/0929866524666170728151401 . PMID 28758593 . (2 ) a counter-regulatory or vasodilator pathway comprising angiotensin-converting enzyme 2 (ACE2), Angiotensin-(1-7) [Ang-(1-7)] and Mas receptor, which is involved in vasodilation, antiproliferation, anti-hypertrophy, cardioprotective and renoprotective actions.
^ Young D, Waitches G, Birchmeier C, Fasano O, Wigler M (June 1986). "Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains". Cell . 45 5 ): 711–9. doi :10.1016/0092-8674(86 )90785-3 . PMID 3708691 . S2CID 29886272 .
^ Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, et al. (July 2003). "Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas" . Proceedings of the National Academy of Sciences of the United States of America . 100 (14 ): 8258–63. Bibcode :2003PNAS..100.8258S . doi :10.1073/pnas.1432869100 PMC 166216 PMID 12829792 .
^ Santos RA, Ferreira AJ (March 2007). "Angiotensin-(1-7) and the renin-angiotensin system". Current Opinion in Nephrology and Hypertension . 16 2 ): 122–8. doi :10.1097/MNH.0b013e328031f362 . PMID 17293687 . S2CID 32812104 .
^ Santos RA, Ferreira AJ (2006). "Pharmacological effects of AVE 0991, a nonpeptide angiotensin-(1-7) receptor agonist" . Cardiovascular Drug Reviews . 24 doi :10.1111/j.1527-3466.2006.00239.x PMID 17214600 .
External links [ edit ]
t
e
R e t r i e v e d f r o m " https://en.wikipedia.org/w/index.php?title=MAS1_oncogene&oldid=1212935833 " C a t e g o r i e s : ● G e n e s o n h u m a n c h r o m o s o m e 6 ● M e m b r a n e p r o t e i n s t u b s H i d d e n c a t e g o r i e s : ● A r t i c l e s w i t h s h o r t d e s c r i p t i o n ● S h o r t d e s c r i p t i o n i s d i f f e r e n t f r o m W i k i d a t a ● P r o t e i n p a g e s n e e d i n g a p i c t u r e ● W e b a r c h i v e t e m p l a t e w a y b a c k l i n k s ● A l l s t u b a r t i c l e s
● T h i s p a g e w a s l a s t e d i t e d o n 1 0 M a r c h 2 0 2 4 , a t 0 7 : 5 4 ( U T C ) . ● T e x t i s a v a i l a b l e u n d e r t h e C r e a t i v e C o m m o n s A t t r i b u t i o n - S h a r e A l i k e L i c e n s e 4 . 0 ;
a d d i t i o n a l t e r m s m a y a p p l y . B y u s i n g t h i s s i t e , y o u a g r e e t o t h e T e r m s o f U s e a n d P r i v a c y P o l i c y . W i k i p e d i a ® i s a r e g i s t e r e d t r a d e m a r k o f t h e W i k i m e d i a F o u n d a t i o n , I n c . , a n o n - p r o f i t o r g a n i z a t i o n . ● P r i v a c y p o l i c y ● A b o u t W i k i p e d i a ● D i s c l a i m e r s ● C o n t a c t W i k i p e d i a ● C o d e o f C o n d u c t ● D e v e l o p e r s ● S t a t i s t i c s ● C o o k i e s t a t e m e n t ● M o b i l e v i e w
